Skip to main content
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Main navigation - Mobile
1. Sarepta Therapeutics
Sarepta's Exondys therapy not cost-effective for patients: ICER
Thursday, May 23, 2019
Sarepta Therapeutics’ DMD therapy Exondys has already been knocked for its skimpy clinical data. Now a price watchdog says it’s also too expensive.
CHMP endorses Lilly's CGRP Emgality, Spark's Luxturna and more
Friday, September 21, 2018
Emgality will likely chase Amgen and Novartis’ first-in-class Aimovig and Teva's Ajovy in the CGRP migraine field.
Sarepta CEO Ingram nabs $57M in 2017 pay
Monday, May 7, 2018
Sarepta CEO Douglas Ingram may have netted biopharma's biggest 2017 compensation package after six months on the job.
Sarepta’s CEO pick draws praise, takeover talk from analysts
Thursday, June 29, 2017
Sarepta’s new CEO pick, Doug Ingram, wins plaudits for commercial savvy, CNS expertise—and sets the stage for more M&A chatter.
Accelerated FDA approval, pricey drugs make rotten combo, doctors argue
Thursday, May 25, 2017
Should drugs that win conditional FDA approval command the same high prices as products that undergo the full menu of agency scrutiny?
PTC tags Emflaza at $35,000 after discounts
Monday, May 8, 2017
PTC says it'll charge $35,000 for Emflaza, the Duchenne drug it bought from Marathon in March, amid a brouhaha over its $89,000 list price. Is the new sticker low enough?
Doctors ready to roll with Sarepta's $300K DMD med. Are payers?
Wednesday, September 28, 2016
You know that old saw about every med school graduate winning the “Doctor” title? Something similar could apply to Sarepta’s newly approved Duchenne muscular dystrophy med Exondys 51.